1-8 of 8
Lingxiao Li, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Artavazd Arumov, BSc, Piumi Y. Liyanage, BS, Asaad Trabolsi, MD, Lingxiao Li, PhD, Evan R. Roberts, BS, Daniel Bilbao, PhD, Roger M. LeBlanc, PhD, Jonathan H. Schatz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4061.
https://doi.org/10.1182/blood-2019-122599
Published: 2019
Journal Articles

NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation

Elias Drakos, MD PhD Prof., Konstantina Stathopoulou, MSc., Lingxiao Li, PhD, Daniel Bilbao, Vasiliki Leventaki, Pedro Farrajota Neves Da Silva, MD, Vasileios Atsaves, PhD, Anders Österborg, MD PhD, L. Jeffrey Medeiros, MD, Francisco Vega, MD PhD, Jonathan H. Schatz, MD, Francois Claret, PhD, George Z. Rassidakis, MD PhD Prof.
Journal: Blood
Blood (2019) 134 (Supplement_1): 2796.
https://doi.org/10.1182/blood-2019-130457
Published: 2019
Journal Articles

CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients

Soumya Sundara Rajan, MSc, Lingxiao Li, PhD, Kranthi Kunkalla, Amit Dipak Amin, PhD, Nitin Agarwal, Francisco Vega, MD PhD, Jonathan H. Schatz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 779.
https://doi.org/10.1182/blood-2018-99-114692
Published: 2018
Journal Articles

NPM1-ALK Overexpression-Driven Toxicity in ALCL Is Partner Dependent and Mediated By STAT1 Antagonism of STAT3 Survival Signaling, Revealing a Novel Therapeutic Strategy

Soumya Sundara Rajan, M.Sc, Amit Dipak Amin, PhD, Lingxiao Li, PhD, Delphine C. M. Rolland, PharmD, PhD, Haiquan Li, PhD, Soham Puvvada, MD, Yves Lussier, MD, Megan S. Lim, MDPhD, Jonathan H. Schatz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2506.
https://doi.org/10.1182/blood.V130.Suppl_1.2506.2506
Published: 2017
Journal Articles

The Marine Natural Compound Elatol Is a Novel Protein Translation Inhibitor with Potent Activity Against Aggressive Non-Hodgkin Lymphomas

Tara Peters, BA, Joseph Tillotson, PhD, Sarah C Wilmore, BSc, Alison Yeomans, PhD, Graham Packham, PhD, Eli Chapman, PhD, Jonathan H. Schatz, MD, Lingxiao Li, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4112.
https://doi.org/10.1182/blood.V130.Suppl_1.4112.4112
Published: 2017
Journal Articles

Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation

Tara L. Peters, BA, Ana A Tula-Sanchez, PhD, Lingxiao Li, PhD, Praechompoo Pongtornpipat, BS, Mengdie WANG, BS, Nicolette BROWN, BS, Soham D. Puvvada, MD, Jonathan H. Schatz, MD
Journal: Blood
Blood (2014) 124 (21): 4496.
https://doi.org/10.1182/blood.V124.21.4496.4496
Published: 2014
Journal Articles

Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1

Lingxiao Li, PhD, Praechompoo Pongtornpipat, BS, Timothy Tiutan, BS, BA, Samantha L. Kendrick, PhD, Soyoung Park, MD, Daniel O Persky, MD, Lisa M. Rimsza, MD, Soham D. Puvvada, MD, Jonathan H. Schatz, MD
Journal: Blood
Blood (2014) 124 (21): 506.
https://doi.org/10.1182/blood.V124.21.506.506
Published: 2014
Journal Articles

Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom

Lingxiao Li, PhD, Praechompoo Pongtornpipat, Soham D. Puvvada, MD, Jonathan H. Schatz, MD
Journal: Blood
Blood (2013) 122 (21): 1831.
https://doi.org/10.1182/blood.V122.21.1831.1831
Published: 2013